Oxurion Competitors and Similar CompaniesClear all
Oxurion's competitors and similar companies include Aerie Pharmaceuticals, Alnylam, Catalyst Pharmaceuticals and ANI Pharmaceuticals.
 Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. |  ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. | |
Founding Date | Founding Date 1991 | Founding Date 2005 | Founding Date 2002 | Founding Date 2002 | Founding Date 1996 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Leuven, BE HQ Dublin 8, IE | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | Locations Coral Gables, US HQ | Locations Baudette, US HQ Oakville, CA Baudette, US | |
Employees | Employees 785% increase | Employees 3808% increase | Employees 1,32324% increase | Employees 7649% increase | Employees 33813% increase |
Valuation ($) | Valuation ($) 626.1 k | Valuation ($) 722.2 m | Valuation ($) 36.5 b | Valuation ($) 2.6 b | Valuation ($) 1.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $589m (FY, 2025) | Revenue (est.) $883.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) | Cost of goods $677.2m (FY, 2025) | Cost of goods $87.3m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit €937k (FY, 2025) | Gross profit N/A | Gross profit $3b (FY, 2025) | Gross profit $501.7m (FY, 2025) | Gross profit N/A |
Net income | Net income (€3.7m) (FY, 2025) | Net income ($74.8m) (FY, 2021) | Net income $313.7m (FY, 2025) | Net income $214.3m (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 3.9m | Total funding raised $ 388.6m | Total funding raised $ 1.5b | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Aerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyCatalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View companyANI Pharmaceuticals
HQ
Baudette, US
Employees
338↑ 13% increase
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View company